AAD: Subcutaneous amlitelimab aids atopic dermatitis outcomes through week 24

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis (AD), according to the results of three phase 3 studies presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

…